Many of our patients experience not only weight loss but also enhanced energy, improved mobility, and a better quality of life
Many insurers cover treatment for Duchenne muscular dystrophy, which can top $1 million a year, but there are fewer than 50,000 patients with the disease in the United States, according to Pfizer, and not all are candidates for the treatment
102 The FDA set several usage restrictions upon the initial approval of Tanzeum (albiglutide), reflecting considerations of suitability and safety for specific patient groups
We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions